Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359869 | 1.00 | NPSR1 (0.43) | NPSR1MEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL26516521 | 0.82 | KMT2A (0.43) | NPSR1MEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL26115418 | 0.82 | LMNA (0.46) | NPSR1MEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL1396133 | 0.81 | NPSR1 (0.57) | NPSR1MEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL31359827 | 0.81 | NPSR1 (0.57) | NPSR1MEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4122604 | 0.80 | PDE4A (0.47) | NPSR1MEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4834600 | 0.78 | ALDH1A1 (0.49) | NPSR1MEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4834418 | 0.77 | CNR1 (0.45) | NPSR1MEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4842122 | 0.75 | CYP11B2 (0.56) | SMN1; SMN2ALDH1A1KDM4ENPC1CYP1A2 | |
| SCHEMBL4834009 | 0.75 | DHODH (0.48) | NPSR1MEN1KMT2ASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA DEVELOPMENT CENTER AMERICAS, INC. | 2025-11-06 | — | — | US | disclosed |
| EP-4504733-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023194964-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023194964-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | WO | disclosed |
| US-7645756-B2 | 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | NPSR1 1896/4885MEN1 3679/4885KMT2A 4387/4885 |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | NPSR1 23/4885MEN1 1259/4885KMT2A 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.